Many adults hear about testosterone therapy (“TRT”) and sermorelin when they’re looking for options to feel better with age. This guide explains what each therapy is, where they do and don’t fit, and why clear indications and monitoring matter. This page is educational and not medical advice.
Key Points
-
TRT is a prescription therapy approved only for men with clinically diagnosed hypogonadism due to specific medical causes, confirmed by testing. It is not approved for age-related “low T,” general vitality, weight loss, or performance goals. Recent FDA label updates retained those limits and added blood-pressure warnings for certain products.
-
Sermorelin (GHRH 1-29) previously had a marketed brand (Geref) that was later discontinued; FDA determined it was not withdrawn for safety/efficacy reasons, but today’s compounded sermorelin products are not FDA-approved.
-
Claims that TRT + sermorelin “build muscle,” “enhance performance,” or “reverse aging” overstate the evidence and may be inappropriate. Major endocrine groups caution against GH-axis therapies for anti-aging/performance uses.
What TRT Is (and Isn’t)
What it is: Prescription testosterone for men with confirmed hypogonadism, based on symptoms, exam, and repeated morning labs, with ongoing monitoring.
What it isn’t: An FDA-approved treatment for age-related low testosterone, vitality, or athletic/performance goals. The FDA’s 2025 label changes kept the “limitation of use” for age-related low T and added BP warnings to some forms. U.S. Food and Drug Administration
What Sermorelin Is (and Isn’t)
What it is: A synthetic fragment of growth-hormone–releasing hormone (GHRH 1-29) that can stimulate pituitary GH release. A brand (Geref) was previously marketed and then discontinued; FDA lists it among discontinued drug products and notes the withdrawal was not for safety/efficacy reasons. Federal Register
What it isn’t: An FDA-approved, commercially available therapy today. Compounded sermorelin preparations in the market are not FDA-approved and lack standardized labeling regarding safety, effectiveness, or quality. Professional bodies caution against GH-axis therapies for anti-aging/performance uses. Federal Register Public Inspection
“Combining TRT and Sermorelin”: Set Realistic Expectations
While some clinics market the two together, high-quality evidence specifically supporting combined use for superior outcomes is limited. If a patient independently meets criteria for each condition (e.g., a man with clinically diagnosed hypogonadism and a separate, guideline-supported GH-axis diagnosis), treatment decisions are made separately, with indication-aligned dosing and monitoring. Blanket claims about muscle/strength/performance or “anti-aging” are not appropriate. Endocrine Society
Safety, Monitoring, and Conversations to Have
-
TRT (men with hypogonadism): Discuss baseline cardiovascular risk, BP monitoring per recent label changes, hematocrit/hemoglobin, and age-appropriate prostate screening. U.S. Food and Drug Administration
-
GH-axis considerations: Adult GH deficiency requires guideline-based testing; if diagnosed, the FDA-approved therapy is recombinant human GH (somatropin)—not sermorelin. Professional guidelines outline when to test and treat. Dr. Mohsen Eledrisi
-
Avoid promises: Skip “before/after” imagery and outcome guarantees (e.g., “enhanced muscle mass and strength,” “faster recovery,” “anti-aging effects”). Keep language neutral and individualized.
Our Approach at Body Balance Medical
We keep care diagnosis-led. If hypogonadism is suspected, we follow guideline evaluation and discuss on-label options and monitoring. If patients ask about GH-axis symptoms, we address common causes first and only consider guideline-supported testing; where a product is not FDA-approved (e.g., compounded sermorelin), we’re transparent about uncertainties and safety. We do not promote performance claims or prohibited products.
Schedule a consultation with Body Balance today!
FAQs
Is TRT approved for age-related low testosterone or performance?
No. In the U.S., TRT is approved only for certain men with medically caused hypogonadism; labels retain the limitation against age-related low T, with new BP warnings on some forms. U.S. Food and Drug Administration
Is sermorelin FDA-approved today?
No. A prior brand (Geref) is discontinued; compounded sermorelin products currently in use are not FDA-approved. Federal Register
Are GH-axis therapies recommended for anti-aging or performance?
Major endocrine statements caution against anti-aging/performance uses due to limited evidence and potential risks. Endocrine Society
